fludarabine and pyrimidinones

fludarabine has been researched along with pyrimidinones in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N	1
Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D	1

Trials

1 trial(s) available for fludarabine and pyrimidinones

Article	Year
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood, 2010, Aug-12, Volume: 116, Issue:6 Topics: Administration, Oral; Aged; Antineoplastic Agents; Apoptosis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Phosphoric Monoester Hydrolases; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Severity of Illness Index; Vidarabine	2010

Article

Year

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Blood, 2010, Aug-12, Volume: 116, Issue:6

Topics: Administration, Oral; Aged; Antineoplastic Agents; Apoptosis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Phosphoric Monoester Hydrolases; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Severity of Illness Index; Vidarabine

2010

Other Studies

1 other study(ies) available for fludarabine and pyrimidinones

Article	Year
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood, 2009, Aug-20, Volume: 114, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine	2009

Article

Year

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

Blood, 2009, Aug-20, Volume: 114, Issue:8

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2009